ClearPoint Neuro, Inc.
CLPT Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 23, 2026
$9.14
KIRA · Stoqly’s AI analyst, in plain words
- ClearPoint Neuro, Inc. had $37.0M of revenue in fiscal 2025, up 17.8% on the year before. Over five years, revenue changed +23.6% a year on average.
- Its operating margin was −65.4%, down 2.5 pts: of every 100 in sales, about −65 is left after running the business.
- ClearPoint Neuro, Inc. lost $25.5M in fiscal 2025.
- Free cash flow was −$24.4M in fiscal 2025, −66.1% of revenue.
- ClearPoint Neuro, Inc. owes $3.2M more than it holds in cash.
Market cap
$276M
P/E
—
Revenue
$37.0M
Net income
−$25.5M
Free cash flow
−$24.4M
Operating margin
−65.4%
ClearPoint Neuro, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+17.8%
Yes. Sales grew 17.8% last year.
Does it make a profit?
−69.1%
No. It lost money last year.
Does profit turn into cash?
−66.1%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What ClearPoint Neuro, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 17, 2026
- Legal name
- ClearPoint Neuro, Inc.
- CIK
- 0001285550
ClearPoint Neuro, Inc. · CLPT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $16.3M | $20.6M | $24.0M | $31.4M | $37.0M |
| Revenue growth | 27.0% | 26.1% | 16.6% | 31.0% | 17.8% |
| Net interest income | — | −$0.1M | $0.4M | $0.9M | — |
| Gross margin | 68.2% | 65.8% | 56.8% | 60.9% | 61.4% |
| Operating margin | −82.1% | −79.5% | −93.7% | −62.9% | −65.4% |
| Net income | −$14.4M | −$16.4M | −$22.1M | −$18.9M | −$25.5M |
| Net margin | −88.4% | −80.0% | −92.2% | −60.3% | −69.1% |
| Diluted EPS | −$0.69 | −$0.68 | −$0.90 | −$0.70 | −$0.90 |
| Cash | |||||
| Cash from operations | −$12.7M | −$16.2M | −$13.7M | −$9.0M | −$23.9M |
| Capital expenditure | $0.2M | $0.3M | $0.7M | $0.3M | $0.5M |
| Free cash flow | −$12.9M | −$16.4M | −$14.4M | −$9.2M | −$24.4M |
| FCF margin | −78.9% | −79.9% | −60.3% | −29.4% | −66.1% |
| Share count change | 30.8% | 16.6% | 1.8% | 9.8% | 4.8% |
| Debt and strength | |||||
| Cash and short-term investments | $54.1M | $37.5M | $23.1M | $20.1M | $45.9M |
| Debt incl. finance leases | $9.8M | $9.9M | $9.9M | — | $49.1M |
| Shareholders' equity | $48.8M | $36.9M | $21.2M | $25.4M | $28.0M |
| Current ratio | 13.0x | 7.5x | 4.9x | 3.2x | 5.9x |
| Interest coverage | −13.7x | −201.6x | — | −38.1x | −10.1x |
| Returns and quality | |||||
| Return on capital | −234.0% | −138.9% | −222.2% | — | −61.2% |
| Return on equity | −56.3% | −38.4% | −76.1% | −81.2% | −95.6% |
| Return on tangible equity | −29.5% | −44.6% | −104.3% | −105.6% | −385.5% |
| Piotroski F-score | 4 | 2 | 2 | 4 | 4 |
| Altman Z'' | 0.7 | −3.5 | −11.3 | −13.5 | −4.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$2.5M
4 insiders
Of sales under plans
90%
$2.2M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
ClearPoint Neuro, Inc. · CLPT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $9.14 a share, the company is worth $276M.
Source: SEC EDGAR XBRL filings (CIK 0001285550). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.